Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk about a new online marketplace to trade animal parts for research, an initiative to ensure ethics in AI-driven protein synthesis, and more.
Amylyx and the ALS aftermath
Friday was an unfortunate, ground-shifting day for the ALS community. The failure of Amylyx Pharmaceuticals’ drug Relyvrio to show any benefit over a placebo in a large clinical trials will almost certainly lead to the withdrawal of the medicine from the market.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect